ERNA or IART or SIBN
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ERNA’s FA Score shows that 0 FA rating(s) are green whileIART’s FA Score has 1 green FA rating(s), and SIBN’s FA Score reflects 0 green FA rating(s).
- ERNA’s FA Score: 0 green, 5 red.
- IART’s FA Score: 1 green, 4 red.
- SIBN’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ERNA’s TA Score shows that 3 TA indicator(s) are bullish while IART’s TA Score has 4 bullish TA indicator(s), and SIBN’s TA Score reflects 7 bullish TA indicator(s).
- ERNA’s TA Score: 3 bullish, 4 bearish.
- IART’s TA Score: 4 bullish, 5 bearish.
- SIBN’s TA Score: 7 bullish, 4 bearish.
Price Growth
ERNA (@Biotechnology) experienced а +5.29% price change this week, while IART (@Medical Specialties) price change was +5.96% , and SIBN (@Medical Specialties) price fluctuated +13.01% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +0.93%. For the same industry, the average monthly price growth was +6.80%, and the average quarterly price growth was -5.97%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +1.18%. For the same industry, the average monthly price growth was +4.70%, and the average quarterly price growth was +0.88%.
Reported Earning Dates
ERNA is expected to report earnings on Mar 12, 2025.
IART is expected to report earnings on Jul 23, 2025.
SIBN is expected to report earnings on Aug 11, 2025.
Industries' Descriptions
@Biotechnology (+0.93% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Medical Specialties (+1.18% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| ERNA | IART | SIBN | |
| Capitalization | 15.4M | 2.77B | 672M |
| EBITDA | -36.12M | 256M | -34.45M |
| Gain YTD | -25.510 | -40.432 | 32.596 |
| P/E Ratio | N/A | 41.30 | N/A |
| Revenue | 582K | 1.54B | 139M |
| Total Cash | 1.73M | 309M | 166M |
| Total Debt | 684K | 1.68B | 39M |
ERNA | IART | SIBN | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 5 | 2 | 31 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 63 Fair valued | 80 Overvalued | 44 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | 80 | |
SMR RATING 1..100 | 100 | 90 | 92 | |
PRICE GROWTH RATING 1..100 | 65 | 93 | 37 | |
P/E GROWTH RATING 1..100 | 100 | 7 | 100 | |
SEASONALITY SCORE 1..100 | n/a | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SIBN's Valuation (44) in the Medical Specialties industry is in the same range as ERNA (63) and is somewhat better than the same rating for IART (80). This means that SIBN's stock grew similarly to ERNA’s and somewhat faster than IART’s over the last 12 months.
SIBN's Profit vs Risk Rating (80) in the Medical Specialties industry is in the same range as ERNA (100) and is in the same range as IART (100). This means that SIBN's stock grew similarly to ERNA’s and similarly to IART’s over the last 12 months.
IART's SMR Rating (90) in the Medical Specialties industry is in the same range as SIBN (92) and is in the same range as ERNA (100). This means that IART's stock grew similarly to SIBN’s and similarly to ERNA’s over the last 12 months.
SIBN's Price Growth Rating (37) in the Medical Specialties industry is in the same range as ERNA (65) and is somewhat better than the same rating for IART (93). This means that SIBN's stock grew similarly to ERNA’s and somewhat faster than IART’s over the last 12 months.
IART's P/E Growth Rating (7) in the Medical Specialties industry is significantly better than the same rating for SIBN (100) and is significantly better than the same rating for ERNA (100). This means that IART's stock grew significantly faster than SIBN’s and significantly faster than ERNA’s over the last 12 months.
| ERNA | IART | SIBN | |
|---|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 61% | 2 days ago 72% |
| Stochastic ODDS (%) | 2 days ago 89% | 2 days ago 59% | 2 days ago 78% |
| Momentum ODDS (%) | 2 days ago 82% | 2 days ago 73% | 2 days ago 75% |
| MACD ODDS (%) | 2 days ago 85% | 2 days ago 70% | 2 days ago 78% |
| TrendWeek ODDS (%) | 2 days ago 84% | 2 days ago 60% | 2 days ago 79% |
| TrendMonth ODDS (%) | 2 days ago 85% | 2 days ago 72% | 2 days ago 80% |
| Advances ODDS (%) | 2 days ago 85% | 13 days ago 60% | 3 days ago 78% |
| Declines ODDS (%) | 7 days ago 90% | 8 days ago 74% | 15 days ago 80% |
| BollingerBands ODDS (%) | 2 days ago 86% | 2 days ago 62% | 2 days ago 68% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 62% | 2 days ago 70% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| RTXCX | 12.27 | 0.04 | +0.33% |
| Russell Inv Tax-Managed Real Assets C | |||
| MYSIX | 16.80 | N/A | N/A |
| Victory Trivalent International Sm-Cp Y | |||
| DMCYX | 30.15 | N/A | N/A |
| BNY Mellon Opportunistic Midcap Value Y | |||
| PAXDX | 9.91 | N/A | N/A |
| Impax Global Sustainable Infras Inv | |||
| RIRCX | 73.15 | -0.05 | -0.07% |
| American Funds Capital Income Bldr R3 | |||
ERNA and
Correlation & Price change
A.I.dvisor indicates that over the last year, ERNA has been loosely correlated with CGEN. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ERNA jumps, then CGEN could also see price increases.
| Ticker / NAME | Correlation To ERNA | 1D Price Change % | ||
|---|---|---|---|---|
| ERNA | 100% | +4.29% | ||
| CGEN - ERNA | 39% Loosely correlated | +2.27% | ||
| MDGL - ERNA | 36% Loosely correlated | -1.80% | ||
| IBIO - ERNA | 32% Poorly correlated | +1.09% | ||
| SMMT - ERNA | 31% Poorly correlated | -2.57% | ||
| CYTK - ERNA | 29% Poorly correlated | -4.73% | ||
More | ||||
IART and
Correlation & Price change
A.I.dvisor indicates that over the last year, IART has been loosely correlated with MASI. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if IART jumps, then MASI could also see price increases.
| Ticker / NAME | Correlation To IART | 1D Price Change % | ||
|---|---|---|---|---|
| IART | 100% | -1.17% | ||
| MASI - IART | 45% Loosely correlated | -1.22% | ||
| ITGR - IART | 40% Loosely correlated | +0.25% | ||
| ZBH - IART | 39% Loosely correlated | -0.74% | ||
| CNMD - IART | 39% Loosely correlated | -1.12% | ||
| AZTA - IART | 38% Loosely correlated | -1.41% | ||
More | ||||
SIBN and
Correlation & Price change
A.I.dvisor indicates that over the last year, SIBN has been loosely correlated with AORT. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if SIBN jumps, then AORT could also see price increases.
| Ticker / NAME | Correlation To SIBN | 1D Price Change % | ||
|---|---|---|---|---|
| SIBN | 100% | -1.01% | ||
| AORT - SIBN | 47% Loosely correlated | +0.49% | ||
| UFPT - SIBN | 43% Loosely correlated | +1.46% | ||
| KIDS - SIBN | 41% Loosely correlated | -0.26% | ||
| QTRX - SIBN | 40% Loosely correlated | -19.02% | ||
| LAB - SIBN | 40% Loosely correlated | -1.72% | ||
More | ||||